Viatris Inc (VTRS)
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Last price
- $17.44
- As of
Kresmion compiles this page from VTRS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Viatris Inc (VTRS): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-08.
See the full VTRS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VTRS on one page. Preview it with sample data, then open it live with a free account.
Preview the VTRS dossierActive signals for VTRS
- highCONSENSUS_BUY
4 tracked funds increased VTRS this 2026Q2, institutional consensus
- highCONSENSUS_SELL
5 tracked funds reduced VTRS this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 54% of VTRS (2026Q2)
- highCONSENSUS_SELL
4 tracked funds reduced VTRS this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 97% of VTRS (2026Q2)
FREE, NO ACCOUNT
Every signal on VTRS, as it fires
You are seeing 5 of 26 signals recorded on VTRS since 2026-05-05.
The five above landed across 2 days. The other 21 were recorded on 4 other days. 18 of the 26 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VTRS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Bridgewater Associates, LPCUSIP 92556V106 · 2026Q2 | $27M | 0.11% | , |
| D. E. Shaw & Co., Inc.CUSIP 92556V106 · 2026Q2 | $12.6M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 92556V106 · 2026Q2 | $8.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 92556V106 · 2026Q2 | $8M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 92556V106 · 2026Q2 | $5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 92556V106 · 2026Q2 | $3.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VTRS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VTRS against its peers
VTRS's operating margin of -18.7% ranks in the 24th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | VTRS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 14.3B USD | 883M USD | 80 | 21 |
| Gross margin | 35.2% | 62.8% | 17 | 8 |
| Operating margin | -18.7% | 10.5% | 24 | 18 |
| Net margin | -24.7% | 4.8% | 20 | 22 |
| Return on equity | -23.9% | 9.0% | 23 | 23 |
| P / E | n/a | 19.1x | n/a | 11 |
| 1 year | 75.6% | 22.8% | 86 | 24 |
Peers (25): JAZZ, ZTS, CORT, TEVA, AXSM, AMRX, GSK, OGN, AMLX, TARS, BMY, SUPN, PFE, NVO, LQDA, BHC, HRMY, XERS, TRVI, GPCR, NUVB, ANIP, AZN, OCUL, PAHC. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VTRS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VTRS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VTRS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.